Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This Study aims to evaluate the efficacy and safety of CDA-2 in the treatment of
International Prognostic Scoring System (IPSS) Lower/Intermediate-risk myelodysplastic
syndrome (MDS) in Chinese patients.